# SUPPLEMENTAL WORK - SARS-COV-2 PRECLINICAL WORK

> **NIH NIH N01** · CHRYSALIS BIOTHERAPEUTICS, INC. · 2020 · $1,500,152

## Abstract

Chrysalis proposes to repurpose their regenerative drug, TP508, to treat COVID-19, due to its ability to reduce effects of acute lung injury, prevent normal tissue damage and reduce inflammation.  TP508 has an existing efficacy profile in tissue regeneration clinical trials, an extensive safety profile (600 human subjects with no adverse effects), and is GMP manufactured with sufficient inventory to enter COVID-19 clinical trials. The drug addresses underlying causes of ARDS, including loss of endothelial function.

## Key facts

- **NIH application ID:** 10259992
- **Project number:** 272201700011C-P00011-9999-2
- **Recipient organization:** CHRYSALIS BIOTHERAPEUTICS, INC.
- **Principal Investigator:** LAURIE SOWER
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $1,500,152
- **Award type:** —
- **Project period:** 2020-06-05 → 2021-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10259992

## Citation

> US National Institutes of Health, RePORTER application 10259992, SUPPLEMENTAL WORK - SARS-COV-2 PRECLINICAL WORK (272201700011C-P00011-9999-2). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10259992. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*